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Abstract
Background: Postpartum haemorrhage (PPH) is responsible for about 100,000 maternal deaths every year, most of
which occur in low- and middle-income countries. Tranexamic acid (TXA) reduces bleeding by inhibiting the
enzymatic breakdown of fibrin blood clots. TXA decreases blood loss in surgery and reduces death due to
bleeding after trauma. When given within 3 h of birth, TXA reduces deaths due to bleeding in women with
PPH. However, for many women, treatment of PPH is too late to prevent death. Over one third of pregnant
women in the world are anaemic and many are severely anaemic. These women have an increased risk of
PPH and suffer more severe outcomes if PPH occurs. There is an urgent need to identify a safe and effective
way to reduce postpartum bleeding in anaemic women.
Methods/design: The WOMAN-2 trial is an international, multicentre, randomised, double-blind, placebo-controlled
trial to quantify the effects of TXA on postpartum bleeding in women with moderate or severe anaemia. Ten thousand
women with moderate or severe anaemia who have given birth vaginally will be randomised to receive 1 g of TXA or
matching placebo by intravenous injection immediately (within 15min) after the umbilical cord is cut or clamped. The
primary outcome is the proportion of women with a clinical diagnosis of primary PPH. The cause of PPH will
be described. Data on maternal health and wellbeing, maternal blood loss and its consequences, and other
health outcomes will be collected as secondary outcomes. The main analyses will be on an ‘intention-to-treat’
basis, irrespective of whether the allocated treatment was received. Results will be presented as appropriate
effect estimates with a measure of precision (95% confidence intervals). Subgroup analyses will be based on
the severity of anaemia (moderate versus severe) and type of labour (induced or augmented versus spontaneous). A
study with 10,000 patients will have over 90% power to detect a 25% relative reduction from 10 to 7.5% in PPH. The
trial will be conducted in hospitals in Africa and Asia.
Discussion: The WOMAN-2 trial should provide reliable evidence for the effects of TXA for preventing postpartum
bleeding in women with anaemia.
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Background
Postpartum haemorrhage (PPH) is a leading cause of
maternal mortality and morbidity. PPH follows 6 to 10%
of all births and accounts for around 100,000 maternal
deaths every year [1–3]. Ninety-nine percent of deaths
are in low- and middle-income countries (LMICs) [4].
Many women who survive experience severe morbidity.
Some women need surgery to control the bleeding (e.g.
exploratory laparotomy, uterine artery ligation, brace su-
tures) and many require a hysterectomy, thus removing
the possibility of having more children. Severe morbidity
due to PPH interferes with breastfeeding and bonding
[5]. PPH is a frightening experience and some women
develop post-traumatic stress disorder [6].
Many women with PPH are given a blood transfusion.
However, blood is a scarce and costly resource in LMICs
and access to safe blood is limited. The blood donation
rate in Africa is 5 per 1000 population compared to 47 per
1000 population in the USA and it is estimated that 35 of
the 40 sub-Saharan countries collect less than half of the
donor blood required to meet their population needs [7].
Even when blood is available, because of problems with
screening, recipients are at risk of blood-borne infections
and adverse transfusion reactions are common.
Anaemia is a cause and consequence of PPH. A cohort
study in Assam, India found that women with moderate
or severe anaemia had a greatly increased risk of PPH
[8]. Women with moderate anaemia had a 50% increased
risk of PPH, whereas those with severe anaemia had a
tenfold increased risk. The reasons for the increased risk
is unclear but some researchers think that anaemic
women are more susceptible to uterine atony due to im-
paired oxygen transport to the uterus. Anaemic women
experience worse outcomes after PPH. An international
survey of 275,000 women found that severe maternal
outcomes after PPH were nearly three times more com-
mon in anaemic than in non-anaemic women [9]. Even
moderate bleeding can be life-threatening in anaemic
women. Excessive bleeding after childbirth worsens ma-
ternal anaemia, raising the possibility of a vicious circle
of bleeding and adverse outcomes. Fatigue due to an-
aemia limits a mother’s wellbeing and her ability to care
for her children [10]. Despite efforts to prevent anaemia,
many women labour with low haemoglobin (Hb) levels.
Worldwide, over 32 million pregnant women are an-
aemic, about 800,000 of whom are severely anaemic
[11]. The prevalence is highest in countries in central
and West Africa as well as in South Asia where about
half of pregnant woman are anaemic and it poses a se-
vere public health problem [11, 12]. There is an urgent
need to find an effective way to reduce postpartum
bleeding in anaemic women.
Tranexamic acid (TXA) is a synthetic analogue of the
amino acid lysine, which inhibits fibrinolysis by blocking
the lysine binding sites on plasminogen. TXA reduces sur-
gical bleeding and death due to bleeding in trauma pa-
tients. The WOMAN trial assessed the effects of TXA in
20,060 women with PPH [13]. TXA significantly reduced
death due to bleeding with no adverse effects. When given
within 3 h of birth, TXA reduced death due to bleeding by
nearly one third (Relative Risk (RR) = 0.69, 95% CI 0.52 to
0.91; P = 0.008). However, for many women, treatment is
too late to prevent death from PPH. Most PPH deaths
occur in the first hours after giving birth and women with
anaemia are at increased risk. Whilst there have been
some trials of TXA for the prevention of PPH, most have
serious flaws and very few collected data on maternal
wellbeing. Most of the trials are small, low-quality, single-
centre studies and only one was prospectively registered.
Many trials were not properly randomised and were
imbalanced for key prognostic variables. Furthermore,
several of the trial reports contained important errors or
inconsistencies and at least two trials did not have ethics
approval. There is very little reliable evidence about the ef-
fectiveness and safety of TXA for preventing postpartum
bleeding, especially in high-risk anaemic women.
The WOMAN-2 trial should determine the effects of
TXA in women with moderate or severe anaemia who give
birth vaginally. For pregnant women, the World Health Or-
ganisation (WHO) defines moderate anaemia as Hb levels
of 70–99 g/L and severe anaemia as Hb levels lower than
70 g/L [14]. Women with anaemia are at increased risk of
PPH and experience worse outcomes should PPH occur.
By including women with moderate or severe anaemia, par-
ticipating women have the potential to benefit from the trial
treatment. Results from clinical trials of TXA in elective
surgery show that TXA reduces blood loss by about one
third irrespective of baseline blood loss [15]. In other
words, TXA treatment seems to move the entire distribu-
tion of bleeding towards reduced blood loss. If this is also
the case in postpartum anaemic women, then trial partici-
pants have the potential to benefit whether or not they ex-
perience PPH, since even moderate or mild blood loss can
have adverse health consequences in anaemic women.
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Around 10,000 women with moderate or severe an-
aemia giving birth in hospitals primarily in Africa and
Asia will be randomly allocated to receive TXA or
matching placebo after the umbilical cord is cut or
clamped. Although there is no evidence of any adverse
effects on the baby, by randomising women after cut-
ting or clamping the umbilical cord, any risk associated
with placental transfer of the trial treatment to the baby
is removed. The umbilical cord will be cut or clamped
in the usual way and the timing will not be affected by
the trial. TXA passes into breast milk in very low con-
centrations and so an antifibrinolytic effect in the baby
is highly unlikely.
How does tranexamic acid prevent excessive blood loss?
The ability to form a blood clot depends on fibrinogen
levels. In both trauma and PPH, a low serum fibrinogen
is a strong predictor of life-threatening bleeding. Fi-
brinogen declines rapidly during bleeding due to its con-
sumption in fibrin clot formation. However, fibrinolysis
due to the activation of plasmin by tissue plasminogen
activator (TPA) worsens fibrinogen depletion by break-
ing down clots. Tissue- plasminogen-activator-mediated
fibrinogenolysis also depletes fibrinogen levels. Early
TXA administration has the potential to prevent exces-
sive blood loss by interrupting the vicious circle of
fibrinolysis and fibrinogen depletion. Women with an-
aemia are at increased risk of bleeding soon after deliv-
ery. If they can be treated with TXA before their
fibrinogen levels fall, severe postpartum bleeding and its
consequences may be prevented.
Rationale for trial
For some women the treatment of PPH is too late to pre-
vent death and severe morbidity. Despite efforts to in-
crease the availability of antenatal care, many women are
anaemic at the time of giving birth and blood for transfu-
sion is often unavailable. There is an urgent need to re-
duce postpartum bleeding and its adverse impacts on
mothers, especially in anaemic women in LMICs. Know-
ing that TXA reduces deaths due to bleeding after PPH
provides reason to believe that it might also prevent PPH.
However, the evidence to date is insufficient to support
the prophylactic use of TXA in routine clinical practice.
Most of the available trials of TXA for preventing PPH are
small and unreliable, and few collect information on ma-
ternal health and wellbeing [16, 17]. One exception is the
TRAAP trial [18] which enrolled 4079 women who were
giving birth vaginally in French hospitals. Women were
randomised to receive 1 g TXA or matching placebo
within 2 min after delivery. Although women who
received TXA were less likely to experience a blood loss
of ≥ 500mL (the primary endpoint), the difference was
not statistically significant (RR = 0.83, 95% CI 0.68 to 1.01;
P = 0.07). Fewer woman in the TXA group received add-
itional uterotonics (RR = 0.75, 95% 0.61 to 0.92; P = 0.006);
however, there were no statistically significant differences
in transfusion, change in Hb or surgical intervention. The
WOMAN-2 trial should provide reliable evidence on the
effects of TXA when used to prevent PPH in anaemic
women in LMICs. Although there was no increase in
thrombotic events with TXA in the WOMAN or TRAPP
trials, the administration of TXA to all women who give
birth vaginally may be inappropriate. There is an increased
risk of venous thrombosis in the postpartum period [19]
and maternal anaemia is an established risk factor [20].
Treating all mothers would involve treating all women
when only a proportion would benefit. However, in an-
aemic women the benefits could outweigh any harms so
that a trial is justified. Inclusion in the trial will be limited
to women giving birth vaginally. For women who give
birth by caesarean section, especially for placenta abnor-
malities, the interval between cord clamping and PPH on-
set is short, often a matter of minutes, so the potential of
TXA to prevent coagulopathy and PPH is limited.
Safety of tranexamic acid
TXA is a widely used treatment with a good safety pro-
file. Although on pathophysiological grounds we might
expect an increased risk of thrombosis with antifibrino-
lytic drugs, randomised trials including over 50,000 par-
ticipants show no increased risk. High doses of TXA
(doses from 7.5 g up to 20 g) have been associated with
seizures in cardiac surgery but there was no increase in
seizures in the CRASH-2 or WOMAN trials, which used
a 1–2 g dose. TXA passes into breast milk in very low
concentrations, approximately 100th of the concentra-
tion in maternal blood. An antifibrinolytic effect in the
breast-fed infant is highly unlikely at this low concentra-
tion [21, 22]. No adverse events (AEs) in breastfed ba-
bies were found in the WOMAN trial. Because TXA will
be given after cutting or clamping the umbilical cord,
there will be no risk of placental transfer to the baby.
Nevertheless, we will collect data on nausea, vomiting,
diarrhoea, maternal thrombotic events, seizures and
thromboembolic events in breastfed babies in all partici-
pants as outcomes. These outcome events will not be re-
ported using the AE reporting procedure.
Objectives
To determine the effects of TXA on postpartum bleed-
ing and other health outcomes in women with moderate
or severe anaemia.
Methods/design
This protocol has been prepared in accordance with
the Standard Protocol Items: Recommendations for
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Interventional Trials (SPIRIT) 2013 Statement (Additional
files 1 and 2: Figures S1 and S2) [23].
Overview
The WOMAN-2 trial is a randomised, parallel-group,
double-blind, placebo-controlled trial of the effects of
TXA in women with moderate or severe anaemia who
are giving birth vaginally. Ten thousand women with
moderate or severe anaemia who are giving birth in
hospitals will be randomised to receive 1 g of TXA or
matching placebo (sodium chloride 0.9%) by intraven-
ous injection immediately and no later than 15 min
after the umbilical cord is cut or clamped (Fig. 1). The
schedule of enrolment, interventions and assessments
according to the SPIRIT 2013 guidelines is presented in
Fig. 2.
Setting
Women from hospitals where anaemia in pregnancy is
common, primarily in Africa and Asia, will be enrolled.
All participating hospitals will have the facilities to pro-
vide comprehensive essential obstetric care as defined by
the WHO.
Number of participants needed
For the purpose of the sample size calculation, a baseline
risk of PPH of 10% was assumed. A trial with 10,000
women would have over 90% power (two-sided alpha =
5%) to detect a clinically important 25% reduction from
10 to 7.5% in PPH. The sample size estimate is based on
two key assumptions (1) the baseline event rate and (2)
the size of the treatment effect. The primary endpoint is
PPH. The prevalence of PPH is estimated at 6% world-
wide but 10% in Africa and Asia [2]. If the event rate is
10% then the trial has 99% power. However, if the event
rate is lower, the study will have less power. For example
if the 6% estimate applies, the trial would have just over
90% power. Planning for the possibility that the event
rate may be lower than anticipated is a sensible precau-
tion. It is also possible that the treatment effect is not as
large as predicted. Although a 25% reduction would be
clinically important, a more modest reduction would
also be worthwhile. The additional power also reduces
the chance that a more modest treatment effect will be
missed. Experience from the WOMAN trial shows that
loss to follow-up will be minimal (less than 1%) and will
not influence trial power. The LSHTM Clinical Trials
Unit (CTU) has successfully recruited large sample sizes
for previous international trials and is experienced at
Fig. 1 Trial overview
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managing recruitment at sites to ensure that target
recruitment is achieved. The main anticipated risk to re-
cruitment to the WOMAN-2 trial is political instability
in the participating countries. The main resource for
mitigating this risk is the large international network of
obstetric clinical trialists that was established during the
WOMAN trial. If political instability prevents the
recruitment of patients in any of the planned settings,
recruitment in other sites will be initiated, thereby redu-
cing the risk.
Identification of participating investigators and trial sites
Participating investigators and trial sites will be identi-
fied from the international network of obstetricians that
was established during the WOMAN trial and includes
hospitals where anaemia in pregnancy is common.
Before the trial can start at any site, all relevant regula-
tory and ethics approvals must be in place and the site
principal investigator (PI) must agree to conduct the
trial according to the Protocol, Good Clinical Practice
(GCP) guidelines and all the relevant regulations. Names
of participating sites will be listed on the trial website
(http://woman2.lshtm.ac.uk/).
Eligibility of participants
Inclusion criteria
Women with moderate or severe anaemia (Hb level
< 100 g/L or packed cell volume (PCV) < 30%), who
have given birth vaginally and for who the respon-
sible clinician is substantially uncertain whether to
use TXA.
Exclusion criteria
 Women who are not legally adult (< 18 years) and
permission not provided by a guardian
 Women with a known allergy to TXA or its excipients
 Women who develop PPH before the umbilical cord
is clamped/cut
Information giving and consent procedure
Wall posters and brief information leaflets (Additional file 3)
will be used to inform pregnant women attending antenatal
clinics and labour wards about the trial. Information may
also be provided in videos. Eligible women with moderate
or severe anaemia will be invited to take part in the trial. If
women are in the active stage of labour and able to give
fully informed consent, written consent will be obtained.
However, many women arrive at hospital in the second
stage of labour. Because these women are more likely to be
anaemic and more likely to have a PPH it will be important
to include these women in the trial. However, they may not
have the physical or mental capacity to give fully informed
consent due to the pain of labour, poor health or the ur-
gency of the situation. In these cases, a clinician will assess
the capacity of the woman and the most appropriate
Fig. 2 Schedule of procedures, events and assessments
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consent procedure will be used for her. An overview of the
consent procedure is provided in Additional file 4.
The consent procedure will be adapted depending on
the clinical situation and the capacity of each woman.
The consent process used will be documented in the
participant’s medical records.
Potentially eligible woman identified in active labour
A member of the site trial team will approach the woman
with the agreement of the primary carer. She will be given
information about the trial (Additional file 5) and the trial
will be discussed in a language she understands. The team
member will explain the purpose of the trial, that it does
not involve any change to her birth plan, and that she will
receive all the usual interventions for preventing PPH and
any other care she needs. The team member will explain
that her participation is voluntary and that if she does not
want to take part that we will respect her views and that
her decision will not affect her care. If she wants to take
part, the team member will obtain written consent. If she
is unable to read or write, the information sheet will be
read to her and she will mark the consent form with a
cross or thumbprint. In this case, an impartial witness
must provide a signature confirming the mark. A copy of
the information sheet and consent form will be given to
the woman. If a woman is in active labour and her
capacity to consent is impaired, for example by analgesia
or pain, consent will be obtained as described in the fol-
lowing section.
Potentially eligible woman identified in the second stage of
labour
Many women in LMICs arrive at hospital in the second
stage of labour. A study in Nigeria found that over one
quarter of women arrived at the labour ward in the sec-
ond stage [24]. Furthermore, women who arrived in the
second stage were more often anaemic and at greater
risk of PPH. However, many of these women will be un-
able to give fully informed consent due to pain, medica-
tion or the urgency of the situation. Fully informed
consent will be obtained if her physical and mental cap-
acity allows. If in the view of the responsible clinician a
woman is unable to give fully informed consent, infor-
mation to her level of capacity will be given and her
verbal agreement obtained in the presence of an impar-
tial witness. If an accompanying person (e.g. her part-
ner or other family members) is present, their views
will be considered but the opinion of the woman will
prevail. Where verbal agreement has been obtained, a
woman can be enrolled into the study. Fully informed
consent for ongoing trial participation will be sought
from the woman as soon as possible after she regains
her full capacity.
Women under 18 years old
If a woman is under 18 years of age, her consent will
be witnessed by a guardian who should be an appro-
priate responsible adult (e.g. her parents, husband,
partner or other family member) who will countersign
the consent form.
Withdrawal of consent
If the woman withdraws a previously given informed
consent, refuses to consent for continuation in the trial,
or if the woman dies and no written consent is available,
her data will be handled as follows:
 Data collected to the point of withdrawal of consent
will be used as part of the intention to treat analysis
 In the event a woman dies and full consent is not
available, data will be collected as per protocol as
the woman would have given her agreement to take
part in the trial. The relevant Ethics Committee will
be informed
Screening and enrolment procedures
Routine clinical screening
Many pregnant women are likely to arrive to give birth
at a participating hospital without antenatal care, or with
low compliance with treatments for anaemia. It is im-
portant for her clinical care that her Hb or PCV value is
known before giving birth. If no test has been done on
admission to give birth, women planning to give birth
vaginally will be offered a standard point-of-care Hb
assessment (HemaCue®). Pregnant women will be in-
formed about the purpose of the test before it is per-
formed and they will have the right to accept or decline
in line with any clinical care being offered. The test will
be provided free of charge. Information on patients
screened will be recorded on a Screening Log.
Women with a moderate or severe anaemia (Hb level
< 100 g/L or PCV < 30%) will be offered the opportunity
to participate in the WOMAN-2 trial.
Baseline screening and eligibility confirmation
Following completion of the appropriate informed con-
sent procedure, data on demographics, anthropometry,
clinical signs, pregnancy and medical history, risk factors
for postpartum haemorrhage, about the birth, about the
baby/ies and baseline treatment plan for the anaemia,
will be collected in the Case Report Form (CRF) Booklet.
Some data will be collected before a woman gives birth
which will assess potential eligibility. Final eligibility will
be confirmed at delivery of the baby’s anterior shoulder
up to when the cord is clamped or cut. This is because
some women who plan to deliver vaginally and have
provided consent may need a caesarean section or may
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develop PPH before the cord is cut or clamped which
will make them ineligible for the trial.
Randomisation
An IT coding expert supported by a statistician who are
not involved in the conduct of the trial will prepare the
randomisation codes. They will give a copy to the spon-
sor’s representative, who is also not associated with the
conduct of the trial, for manual back-up. The IT coding
expert will also send the codes to the trial drug manufac-
turer so that treatment packs can be prepared in accord-
ance with the randomisation list. Trial staff (coordinating
centres and sites) and patients will not have access to the
randomisation codes until final database lock or unless
un-blinding of an individual patient is requested.
Women who are eligible for inclusion will be rando-
mised to receive active (TXA) or placebo (sodium chlor-
ide 0.9%) by intravenous injection.
Once eligibility has been confirmed at delivery of the
baby’s anterior shoulder and up to when the cord is
clamped/cut, the next lowest consecutively numbered
pack will be taken from a box of 20 treatment packs. The
participant is considered randomised to the trial once ad-
ministration of the trial treatment has started. Each site
will keep a log of women they randomise to the trial. Site
investigators will need to explain any out-of-sequence use
of the trial treatment.
Trial treatment
Name and description of Investigational Medicinal Product
(IMP)
Tranexamic acid (TXA) is a synthetic derivative of the
amino acid lysine that exerts an antifibrinolytic effect
through the reversible blockade of lysine binding sites
on plasminogen molecules. TXA is sold under a variety
of trade names for the treatment of bleeding due to
general or local fibrinolysis in adults and children from
1 year of age [25]. TXA would be given in addition to all
the usual interventions for preventing PPH, thus
WOMAN-2 will compare its effects with matching pla-
cebo (sodium chloride 0.9%) to ensure blinding.
Drug administration and dosage schedule
A single dose of 1 g of TXA or placebo (sodium chlor-
ide 0.9%) by intravenous injection will be given imme-
diately after the umbilical cord is cut or clamped, and
no more than 15 min later. There should be no delay in
administering the trial medication after the umbilical
cord is cut or clamped. Each treatment pack contains
two ampoules each containing 500 mg (5 mL) of TXA
or placebo (5 mL), and one sterile 10-mL syringe and
21-G needle. Appropriately qualified staff will prepare
the treatment to be administered by drawing up the
contents of both ampoules into the 10-mL syringe
using the 21-G needle provided. Before administration,
the expiry date will be checked and the randomisation
number confirmed. The contents of both ampoules
(total volume 10 mL) will be administered as a slow
intravenous injection at rate of about 1 mL/min using a
standard local intravenous administration procedure.
In the event of multiple births, the trial drug will be
given after cutting or clamping the umbilical cord of the
last baby.
Known drug reactions and interaction with other therapies
TXA should not be mixed with other medicinal products.
Trial restrictions and the use of concomitant medication
Women should receive all clinically indicated treat-
ments. There is no restriction on the use of concomitant
medication. Many women will develop PPH and these
women should be treated in the usual way, which may
include TXA. If any contra-indication to the trial treat-
ment develops after randomisation, the trial treatment
should be stopped.
Assessment of compliance
Trial team members at each site will record the date and
time of trial treatment administration. If the trial treat-
ment is not given, or is given outside of the prescribed
time period, a reason will be required.
Risks and benefits
TXA reduces the risk of death due to bleeding in
women with PPH. The WOMAN trial randomised
20,060 women with PPH to receive TXA or placebo
[26]. The results show that TXA significantly reduces
death due to bleeding (RR = 0.81, 95% CI 0.65 to 1.00),
particularly when given within 3 h of giving birth (RR =
0.69, 95% CI 0.52 to 0.91). There is also evidence from
randomised trials that TXA improves outcomes in trau-
matic and surgical bleeding. The CRASH-2 trial of
TXA in 20,211 bleeding trauma patients showed that
TXA reduces death due to bleeding when given soon
after injury [27, 28]. Treatment within 3 h of injury re-
duced the risk of death due to bleeding by around 30%
(RR = 0.72, 95% CI 0.63 to 0.83). In surgery, a system-
atic review of 129 randomised trials found that TXA re-
duces the probability of receiving a blood transfusion
by 38% (RR = 0.62, 95% CI 0.58 to 0.68) and average
blood loss by 34% (RR = 0.66, 95% CI 0.65 to 0.67) [15,
29]. There was no increased risk in AEs with TXA in ei-
ther the WOMAN trial, the CRASH-2 trial or the sur-
gical systematic review.
TXA is widely used and well tolerated. Potential
side-effects reported by manufacturers to be associated
with use of TXA according to frequency [30] are
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 Common (≥ 1/100 to < 1/10): diarrhoea, vomiting
and nausea
 Uncommon (≥ 1/1000 to < 1/100): allergic dermatitis
 Rare: hypersensitivity reactions including
anaphylaxis; convulsions; visual disturbances
including impaired colour vision; malaise with
hypotension (generally following an intravenous
injection given too rapidly); arterial or venous
thrombosis
There is some evidence from cohort studies in cardiac
surgery patients that high doses of TXA are associated
with seizures [31–33]. The doses used in these studies
(6–20 g) were substantially higher than the dose that will
be used in the WOMAN-2 trial (1 g). There was no in-
creased risk of seizures with TXA in the two large trials
involving over 40,000 participants that used 1–2 g of
TXA (WOMAN and CRASH-2 trials).
Women in the postpartum period have an increased risk
of thromboembolic events compared with non-pregnant
women. Although the absolute risk of venous thrombosis
is low at around 2 per 1000 woman-years, women in the
postpartum period are four times more likely to suffer a
venous thrombosis than non-pregnant women of the same
age [34]. Although on mechanistic grounds TXA has the
potential to increase the risk of venous thrombosis, rando-
mised trials provide no evidence of any increased risk of
venous thrombosis with TXA. In the WOMAN trial, the
risk of venous thrombosis did not differ significantly
between groups (Table 1). Because severe bleeding is a
strong risk factor for vascular occlusive events and TXA
reduces bleeding, it is possible that TXA reduces (rather
than increases) the risk of thrombosis [35].
TXA is excreted in the urine unchanged with 90% of
the dose excreted in the 12 h after administration.
Plasma concentrations are higher in renal insufficiency
and with repeated dosing there is a risk of accumula-
tion. However, because a single dose of 1 g is used in
the WOMAN-2 trial, there will be no risk of accumula-
tion. Unpublished data from the manufacturer indicate
that TXA passes into breast milk at a concentration of
approximately 100th of the concentration in the maternal
blood and thus an antifibrinolytic effect in the infant is un-
likely [21, 22]. There was no increase in adverse effects in
infants of mothers who received TXA in the WOMAN
trial. Observational studies of TXA use during breastfeed-
ing also found no adverse effects [36].
Investigator’s Brochure (IB)
Information about TXA and the manufacture of the pla-
cebo will be detailed in an Investigator’s Brochure (IB).
The IB will be reviewed annually. Any studies that pro-
vide reliable information on the safety and efficacy of
TXA that would help investigators to assess the risks
and benefits of TXA use, will be included. Additionally,
information on updates from relevant manufacturers of
TXA will be included. Information relevant to the safety
and wellbeing of the participants or the scientific value
of the trial will be communicated to investigators, Data
Monitoring Committee (DMC), Ethics Committees and
regulatory authorities.
Preparation and labelling of medication to be used in the
trial
TXA which has Marketing Authorisation in the United
Kingdom (UK) will be purchased from the open market.
Marketing Authorisation guarantees that drug manufac-
ture and release complies with Good Manufacturing
Practice (GMP). A GMP-certified manufacturer will pre-
pare the matching placebo (sodium chloride 0.9%). Am-
poules and packaging will be identical in appearance for
both TXA and placebo. A clinical trial supply company
will carry out the blinding process and first-stage Quali-
fied Person (QP) release. The blinding process involves
replacing the manufacturer’s label with the clinical trial
label that has the randomisation number (used as pack
identification). Other label text will be identical for TXA
and placebo and complies with requirements for clinical
trials. Checks on a random sample of drug packs to
check the blinding will be carried out to compare known
TXA with blinded samples to confirm which ones are
Table 1 Effect of tranexamic acid (TXA) on thromboembolic events in the WOMAN trial [13]
TXA
(n = 10,033)
Placebo
(n = 9985)
RR (95% CI) P value
Any thromboembolic event 30 (0.3%) 34 (0.3%) 0.88 (0.54 to 1.43) 0.603
Venous events 20 (0.2%) 25 (0.3%) 0.80 (0.44 to 1.43) 0.446
DVT 3 (0.03%) 7 (0.07%) 0.43 (0.11 to 1.65) 0.203
PE 17 (0.2%) 20 (0.2%) 0.85 (0.44 to 1.61) 0.611
Arterial events 10 (0.1%) 9 (0.09%) 1.11 (0.45 to 2.72) 0.827
Myocardial infarction 2 (0.02%) 3 (0.03%) 0.66 (0.11 to 3.97) 0.651
Stroke 8 (0.08%) 6 (0.06%) 1.33 (0.46 to 3.82) 0.599
CI confidence interval, DVT deep vein thrombosis, PE pulmonary embolism, RR Relative Risk
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TXA. The samples will then be un-blinded to assure ac-
curacy of the labelling.
Drug storage and supply
When a site is ready to start, a box containing 20 trial
treatment packs will be sent by the CTU. Thereafter, site
stock level will depend on the site’s average recruitment
rate. Each time a participant is randomised and the ran-
domisation data are entered in the trial database, one
pack from the site’s stock will be automatically deducted.
When stock reaches the site’s minimum level, the CTU
will send another box (or boxes). Sites will need to send
screening and entry data to the CTU as soon as possible
after randomisation (ideally within 24 h). Sites will have
to report all used trial treatments packs and those that
are lost or damaged, to the CTU on a Drug Accountabil-
ity Log (DAL).
At each site, the trial treatment packs will be stored
securely, but in a place where they are accessible to the
trial team for randomisation at all times. Although TXA
is heat stable, it will be stored in a dry place where it is
protected from excessive heat and freezing.
The expiry date of the trial treatment pack will be
printed on the ampoule label, the treatment pack and
the drug box. When a batch of treatment packs is close
to expiry, the PI/trial pharmacist/delegate will be asked
to arrange destruction of affected packs and record this.
When a site is to be closed, the PI/trial pharmacist/dele-
gate will arrange destruction of all unused packs and
confirm disposal to the CTU.
Un-blinding
In general, there should be no need to un-blind the allo-
cated intervention. Un-blinding should occur only in
those rare cases when the clinician believes that a partici-
pant’s management depends importantly upon knowledge
of whether the participant received TXA or placebo. If a
woman in the trial develops PPH, she should receive all
clinically indicated treatments. There should be no need
to un-blind before initiating treatment with TXA. Even if
a woman received 1 g of TXA immediately after giving
birth, TXA has a large therapeutic index and a second 1-g
dose is well within the dosing range. In those few cases
when urgent un-blinding is necessary, a 24-h telephone
service is provided by the CTU. The caller will receive a
voice message, text message or email informing them
whether the woman received TXA or placebo. The inves-
tigator should complete an un-blinding request/report
form within five working days of un-blinding. If a sus-
pected unexpected serious adverse reaction (SUSAR) is
reported, un-blinding may be needed for reporting to
Regulatory Agencies and Ethics Committees.
Outcome measures
Once randomised, we will collect follow-up data even
if the trial treatment is not completed. Data will be
collected within the first 24 h after administration of
the trial treatment and final outcome data will be
collected when a woman is discharged from the ran-
domising hospital, at death or 42 days post randomisa-
tion, whichever occurs first. In the event a woman is
discharged or dies within 24 h, all outcomes will be
assessed at the same time. Adverse events will be col-
lected from administration of the trial medication up
to day 42.
Primary outcome
The primary outcome is a clinical diagnosis of primary
PPH. This may be an estimated blood loss of more than
500 mL or any blood loss sufficient to compromise
haemodynamic stability within 24 h of administration of
trial medication. Haemodynamic instability is based on
clinical judgement and assessed using clinical signs (low
systolic blood pressure, tachycardia, reduced urine out-
put). The cause of PPH will be described.
Secondary outcomes
Maternal blood loss and its consequences:
 Postpartum blood loss (clinical estimation)
 Haemoglobin
 Haemodynamic instability
 Shock index
 Receipt of blood transfusion
 Use of interventions to control postpartum bleeding
(medical and surgical)
Maternal health and wellbeing:
 Symptoms of anaemia (e.g. fatigue, headache,
dizziness, palpitations, breathlessness)
 Exercise tolerance (short 6-min walk test)
 Quality of life (overall wellbeing, ability to care for
herself and her baby, breastfeeding)
Other health outcomes:
 Vascular occlusive events (pulmonary embolism (PE),
deep vein thrombosis (DVT), stroke, myocardial
infarction (MI))
 Organ dysfunction
 Sepsis
 Expected side effects (nausea, vomiting, diarrhoea,
seizure)
 Adverse events
 Death (cause and time to death will be described)
 Length of hospital stay
Ker et al. Trials          (2018) 19:712 Page 9 of 19
 Admission to and time spent in higher level facility
 Status of baby/ies and any thromboembolic events
Data management
Source data
Source documents include, but are not limited to, hos-
pital records (from which medical history, previous and
concurrent medication, clinical outcomes and AEs may
be summarised onto the CRFs), clinical and office log
books, laboratory and pharmacy records, diaries and
correspondence. CRF entries will be considered source
data if the CRF is the site of the original recording (e.g.
quality of life questionnaire, 6-min walk test, breath-
lessness score). Trial data will be kept confidential and
stored securely. On all trial-specific documents, other
than the consent form, the participant will be referred
to by the trial participant screening ID number and not
by name.
Access to source data
Direct access will be granted by participating sites to
authorised representatives from the sponsor, host insti-
tution and the regulatory authorities to permit trial-re-
lated monitoring, audits and inspections.
Data recording and record keeping
All trial data will be entered on to paper CRFs and then
entered onto the trial database by authorised site staff.
The CRFs can be viewed at http://woman2.lshtm.ac.uk/.
The participants will be identified by a unique trial-spe-
cific number. The name and any other identifying detail
will not be included in trial data electronic file used for
analysis or publication. An Investigator’s Site File (ISF)
containing the essential documents for the trial will be
provided by the CTU. The ISF must be updated by the
trial site throughout the course of the trial.
Participant confidentiality
The trial staff will ensure that participants’ confidential-
ity is maintained. Participants will be identified only by a
participant screening ID number on all trial documents
and any electronic database, with the exception of the
paper CRF which remains at participating sites, where
participant initials may be added. All documents will be
stored securely and only accessible by trial staff and
authorised personnel. The trial will comply with relevant
data protection regulations including the UK General
Data Protection Regulation.
Serious breaches and protocol deviations
A serious breach is defined as ‘a breach of GCP or the
trial protocol which is likely to affect to a significant de-
gree (a) the safety or physical or mental integrity of the
subjects of the trial; or (b) the scientific value of the
trial’.
In the event that a serious breach is suspected, the site
must inform the CTU within one working day. The
CTU will report all serious breaches to the relevant
RECs, regulatory authorities within the timeline required
by each participating country.
A protocol deviation is a departure from the ap-
proved protocol’s procedures made with or without
prior approval. Such departures may be major or
minor/administrative in nature. All deviations must be
reported to the CTU within 24 h of it becoming known
to the trial team.
Follow-up and outcome assessment
Trial follow-up ends at hospital discharge, death or 42
days post randomisation, whichever comes first. How-
ever, AE reporting will continue up to day 42. Date and
time of assessments will be recorded.
Primary outcome
The primary outcome will be a clinical diagnosis of PPH
within 24 h of administration of the trial treatment or at
discharge from hospital, whichever is earlier. This may be
an estimated blood loss of more than 500mL or any blood
loss sufficient to compromise haemodynamic stability
within 24 h of delivery. Haemodynamic instability is based
on clinical judgement and assessed using clinical signs
(e.g. low systolic blood pressure, tachycardia, reduced
urine output). The cause of PPH will be described.
Secondary outcomes
The following secondary outcomes will be assessed at
24 h after administration of trial treatment or discharge
from hospital, whichever is earlier:
 Postpartum blood loss: clinical estimation of blood
loss since administration of trial treatment
 Haemoglobin: using HemaCue® point-of-care test
 Haemodynamic instability (within 24 h of
administration of trial medication): presence of
haemodynamic instability based on clinical signs, e.g.
low blood pressure, tachycardia, reduced urine
output requiring intervention (e.g. intravenously
administered fluid)
 Shock index – heart rate/systolic blood pressure:
The lowest recorded systolic blood pressure and the
corresponding heart rate
The following outcomes will be assessed at death, dis-
charge from hospital or 42 days, whichever is earlier:
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 Quality of life: the following parameters will be
measured by questionnaire, overall wellbeing, ability
to care for herself and her baby, and breastfeeding
 Symptoms of anaemia: the following parameters will
be assessed by questionnaire, fatigue, headache,
dizziness, palpitations, breathlessness, flaring of the
alae nasi
 Expected side effects of trial medication: the
following side effects will be recorded, nausea,
vomiting, diarrhoea
 Exercise tolerance: assessed using the 6-min walk
test [37]
 Blood transfusion: number of units given (units
started before administration of trial medication will
not be included). Information on type of transfusion
will be collected.
 Use of interventions to control primary postpartum
haemorrhage (medical and surgical): including
uterotonics, removal of placenta/placental
fragments, intrauterine balloon tamponade,
bimanual uterine compression, external aortic
compression, non-pneumatic anti-shock garments,
uterine artery embolisation, uterine compression su-
ture, hysterectomy and laparotomy to control
bleeding
 Vascular occlusive events: including pulmonary
embolism (PE), deep vein thrombosis (DVT), stroke
and myocardial infarction (MI):
○ PE: diagnosis will be confirmed by radiological
examination
○ DVT: diagnosis will be confirmed by
ultrasound or radiological examination
○ Stroke: defined as ‘a new focal neurological
deficit with signs and symptoms lasting more than
24 h’
○ MI: diagnosis in the presence of one of the
following: (1) electrocardiogram (ECG) showing
unequivocal pathological Q waves and/or ST-
segment elevation or depression in serial
recordings; (2) history of typical or atypical
angina pectoris, together with equivocal
changes on the ECG and elevated enzymes;
(3) history of typical angina pectoris and
elevated enzymes with no changes on the
ECG or not available; (4) fatal cases, whether
sudden or not, with naked-eye appearances of
fresh MI and/or recent coronary occlusion at
necropsy (antemortem thrombus, haemorrhage
into an atheromatous plaque or embolism)
 Organ dysfunction:
○ Cardiovascular dysfunction – shock, cardiac
arrest (absence of pulse/ heart beat and loss of
consciousness), use of continuous vasoactive
drugs, cardiopulmonary resuscitation, severe
hypoperfusion (lactate > 5 mmol/L or > 45 mg/dL),
severe acidosis (pH < 7.1)
○ Respiratory dysfunction – acute cyanosis,
gasping, severe tachypnea (respiratory rate > 40
breaths per min), severe bradypnoea (respiratory
rate < six breaths per min), intubation and
ventilation not related to anaesthesia, severe
hypoxemia (O2 saturation < 90% for ≥ 60 min or
PAO2/FiO2 < 200)
○ Renal dysfunction – oliguria non-responsive to
fluids or diuretics, dialysis for acute renal failure,
severe acute azotaemia (creatinine ≥ 300 μmol/mL
or ≥ 3.5 mg/dL)
○ Coagulation/haematological dysfunction –
failure to form clots, massive transfusion of blood
or red cells (≥ 5 units), severe acute
thrombocytopenia (< 50,000 platelets/mL)
○ Hepatic dysfunction – jaundice in the presence
of eclampsia, severe acute hyper-bilirubinaemia
(bilirubin > 100 μmol/L or > 6.0 mg/dL)
○ Neurological dysfunction – prolonged
unconsciousness (lasting ≥ 12 h)/coma (including
metabolic coma), stroke, uncontrollable fits/status
epilepticus, total paralysis
 Sepsis: diagnosis is based on the presence of both
infection and a systemic inflammatory response
syndrome (SIRS). SIRS requires two or more of the
following: (1) temperature < 36 °C or > 38 °C, (2)
heart rate > 90 beats/min, (3) respiratory rate > 20
breaths/min, (4) white blood cell count < 4 × 109/L
(< 4000/mm3) or > 12 × 109/L (> 12,000/mm3)
 In-hospital death: cause and time of death will be
described
 Length of hospital stay
 Admission to, and time spent in, a higher-level
facility: higher-level facilities include High-
dependency and Intensive Care Units
 Status of baby/ies: the status (dead/alive)
 Any thromboembolic events in breastfed babies
(may include any venous or arterial thrombosis
(thrombosis of limb artery/deep veins, renal artery/
veins, pulmonary embolism, hepatic veins, caval
veins, intracardiac thrombosis, portal vein,
mesenteric veins/artery, cerebral veins, retinal vein,
ischemic stroke, arteries, aorta, myocardial
infarction, microvascular thrombosis from purpura
fulminans or disseminated intravascular coagulation)
 Adverse events
Safety reporting
Outcome events recorded on the CRF Booklet up to
death, discharge or day 42 (whichever is sooner) will not
be included in the definitions of AEs detailed below.
These outcome events include PPH, anaemia, vascular
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occlusive events, organ dysfunction, sepsis, nausea,
vomiting, diarrhea and seizure.
The CTU will present data on these outcome events to
the independent DMC for regular review. These outcome
events will not be reported using the AEs’ reporting pro-
cedure. However, all other medical events fulfilling the AE
definition will be reported up to 42 days after administra-
tion of trial treatment. In the event that a woman is dis-
charged before 42 days, AEs to be reported after discharge
will also include all outcome events.
At discharge, participants will be given an ‘alert card’
that identifies them as a WOMAN-2 participant, and
asked to present this card to anyone providing medical
care after discharge, up to day 42. Instructions to ensure
the AEs’ reporting procedures for the trial are followed
will be detailed on the card. An overview of the safety
reporting procedure is presented in Additional file 6.
Definitions
Adverse event (AE) Any untoward medical occurrence
in a participant to whom a medicinal product has been
administered including occurrences which are not ne-
cessarily caused by or related to that product. An AE
can, therefore, be any unfavourable and unintended sign
(including an abnormal laboratory finding), symptom, or
disease temporally associated with the use of an IMP,.
Adverse reaction (AR) Any untoward and unintended
response in a participant to an IMP which is related to
any dose administered to that participant.
The phrase ‘response to an investigational medicinal
product’ means that a causal relationship between a trial
medication and an AE is at least a reasonable possibility,
i.e. the relationship cannot be ruled out.
Serious adverse event (SAE) A SAE is any untoward
medical occurrence that results in death; is life-threatening;
requires inpatient hospitalisation or prolongation of existing
hospitalisation; results in persistent or significant disability/
incapacity other ‘important medical events’ may also be
considered serious if they jeopardise the participant or
require an intervention to prevent one of the above
consequences.
Serious adverse reaction (SAR) An AE that is both ser-
ious and, in the opinion of the reporting investigator, be-
lieved with reasonable probability to be due to the trial
treatments, based on the information provided.
Suspected unexpected serious adverse reaction (SUSAR)
– a serious adverse reaction, the nature and severity of
which is not consistent with the information about the
medicinal product in question set out in the in the Investi-
gator’s Brochure (IB).
Causality
When completing the AE reporting form, the site PI or
medical delegate will assign a causality using the defini-
tions below:
 Suspected to be related – There is evidence to
suggest a causal relationship with administration of
the trial treatment and the influence of other factors
is unlikely
 Not suspected to be related – There is little or no
evidence to suggest there is a causal relationship
(e.g. the event did not occur within a reasonable
time after administration of the trial treatment).
There is another reasonable explanation for the
event (e.g. the participant’s clinical condition, other
concomitant treatment)
If there is any doubt about the causality, the site PI or
medical delegate will inform the CTU. In the case of dis-
crepant views on causality between the investigator and
others, all parties will discuss the case. In the event that
no agreement is made, both points of view are to be re-
corded and reported onwards as required.
Reporting procedures
Adverse reactions (ARs)/adverse events (AEs) Adverse
Event Reporting Forms will be provided in the CRF
Booklet. Site investigators will report non-serious ARs
and AEs using these.
Serious adverse reactions (SARs)/serious adverse
events (SAEs) Adverse events and ARs which fulfil the
serious criteria will be reported to the CTU within 24 h
of the PI or delegate becoming aware of the event using
the Adverse Event Reporting Form. The form will be
completed and submitted to the CTU with as much de-
tail of the event that is available at that time. If awaiting
further details, a follow-up report will be submitted
promptly upon receipt of any additional information
(but no later than five working days of becoming aware
of the event). The site PI or medical delegate must rec-
ord the event with an assessment of seriousness, causal-
ity and expectedness. Events relating to a pre-existing
condition or any planned hospitalisations for elective
treatment of a pre-existing condition will not be re-
ported as SAEs.
Suspected unexpected serious adverse reactions
(SUSARs) All SAEs assigned by the site PI or medical
delegate as suspected to be related to the trial treatment
and which are unexpected, will be classified as SUSARs
and will be subject to expedited reporting to each par-
ticipating regulatory authority, Ethics Committees and
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the sponsor within seven working days of being reported
to the CTU.
In the case of a SUSAR, the staff at the site will:
 Contact the CTU immediately by telephone or email
to inform them of the event and obtain guidance on
the reporting procedure if needed
 Submit an Adverse Event Report, completed with all
available information (signed and dated) within 24 h,
together with relevant treatment forms and
anonymised copies of all relevant clinical
investigations
 Submit any additional information promptly upon
request
 Emergency contact details for advice on reporting
SAEs and SUSARs can be found in the Investigator’s
Study File
Adverse Event Reporting Forms are submitted in the
following ways:
 Directly via the trial database (see Investigator’s
Study File for full details)
 Fax: + 44 (0)20 7299 4663
 Email: woman2.data@lshtm.ac.uk
AEs considered related to the trial medication as
judged by a site investigator or the CTU will be followed
either until resolution, or the event is considered stable.
Adverse event reporting to the relevant authorities
All SUSARs will be reported by the CTU or sponsor
representative to the relevant regulatory authority and
REC and other parties as applicable. For fatal and
life-threatening SUSARS, this will be done no later than
seven calendar days after the CTU is first made aware of
the reaction. Any additional relevant information will be
reported within eight calendar days of the initial report.
All other SUSARs will be reported within 15 calendar
days. Treatment codes will be un-blinded for specific
participants if required. Site PIs will be informed of all
SUSARs for all studies using TXA sponsored by the
LSHTM, whether or not the event occurred in the
WOMAN-2 trial.
All other AEs will be reported as requested by the
relevant authorities.
Withdrawal criteria
The trial ends for a participant at death or at day 42
whichever occurs first. A participant can leave the trial
at any time. A participant may provide the research team
with the reason(s) for leaving the study, but is not re-
quired to do so. The trial team will inform the partici-
pant to return if she has any medical concerns. If a
participant decides to withdraw from the trial, data col-
lected up to the point of withdrawal will be used as part
of the intention-to-treat analysis, but no other data will
be collected unless the woman gives her permission to
do so. In all cases, her wishes will be respected.
Definition of end of trial
The end of trial will be day 42 of the last participant
randomised.
Monitoring
Risk assessment
Data on side effects that might be associated with an-
aemia, postpartum bleeding or TXA use will be col-
lected and will be presented to the independent DMC.
The trial involves seeking consent, giving the trial
drug using a routine clinical procedure, collecting out-
come information (mostly from the hospital notes), a
Hb estimation, timed walk test, and a quality of life
questionnaire. Prior to discharge, the woman’s Hb
concentration will be measured using a point-of-care
test (HemaCue®). This involves a pinprick blood sam-
ple and takes only a few minutes. This test will provide
clinically useful information for the patient and treat-
ing physicians.
The timed walk test assesses the woman’s functional
exercise capacity. The test measures the distance that a
woman can walk on a flat, hard surface in a period of 6
min. A chair will be placed along the walking area so
she can rest during the test if she chooses to. The results
should give a good indication of the woman’s ability to
carry out her daily physical activities. The test is safe in
patients with cardiopulmonary disease and in frail older
populations. The test will not be done if there is a his-
tory of unstable angina or myocardial infarction in the
past month but these conditions will be extremely rare
in postpartum women. Apart from the trial drug, all
other clinical care will be as per usual practice. For these
reasons, the risk of harm or injury (whether physical,
psychological, social or economic) from participating in
the trial is assessed to be low.
The outcome questionnaire will ask participants
about their mental and physical wellbeing, and breast-
feeding. It is possible that these questions may bring
up feelings for participants such as discomfort, worry
or sadness. Trial staff will be trained to ask the ques-
tions in a sensitive manner and to look for signs of
discomfort in participants. If the trial team member
detects discomfort in any participant, they will ask
permission to continue. If the trial team member has
any concerns about the wellbeing of the participant,
they should refer her back to the treating clinician for
further assessment and ongoing care.
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Central monitoring
The trial will be conducted in accordance with the
current approved protocol, GCP, relevant regulations
guidance provided in the Investigator’s Study File and
the trial’s standard operating procedures.
A detailed monitoring plan will be developed. In sum-
mary, the CTU will closely monitor the trial to ensure
the rights, safety, and wellbeing of the trial participants
and to ensure the accuracy of the data. All coordinating
centres and site trial teams will be trained in the trial
procedures and provide extensive guidance. Central
monitoring methods will be used by the CTU. A sample
of consent forms from all sites will be monitored at the
CTU to make sure they are properly completed. In
addition, data management and statistical checks of data
(central statistical monitoring) will be done to ensure
that trial participants meet the inclusion criteria and trial
treatment is administered in line with the protocol.
Event rates for primary and secondary outcomes will be
monitored. Sites with higher or lower than expected
event rates will be selected for further monitoring.
Quantitative variables (systolic blood pressure (SBP),
heart rate (HR), respiratory rate and blood loss) will be
monitored to check the accuracy of the data. For ex-
ample, the coefficient of variation for the data at each
site will be examined and those where there is any rea-
son for concern will be selected for further monitoring.
Monitoring at local site
Onsite monitoring will be carried out at any site flagged
as high risk on central statistical monitoring and other
central monitoring procedures. Source data verification
will be done on at least 10% of the trial data. Addition-
ally, site self-monitoring will be carried out where
needed. This will involve the PI/delegate at a site moni-
toring themselves against a standardised checklist. The
LSHTM CTU will require investigators and their institu-
tions to provide access to source data and all trial-re-
lated documents for monitoring, audits, Ethics
Committee review and regulatory inspection. All
trial-related and source documents including medical re-
cords, original consent forms and original CRFs must be
kept safely. Investigators must plan in advance of the
trial start where the trial-related documents will be
stored and how they will be accessed. All documents
must be made available when required for monitoring/
audit/inspection during the course of the trial and for up
for 5 years after the end of the overall trial.
Trial closure
Trial closure will happen in the following circumstances:
 Routine – in preparation for the completion of a trial
 Unscheduled – as a result of failure to obtain
continuation funding, DMC request and Trial
Steering Committee agreeing based on negative or
positive findings, findings in other studies that
impact on this trial, or other unforeseen events
(e.g. safety concerns, civil unrest, etc.)
Statistics and data analysis
A detailed Statistical Analysis Plan (SAP) will be drafted
and agreed with the DMC for their ongoing review and
will be finalised before the trial database is locked for
final analysis.
Main analysis
Analyses will be on an ‘intention-to-treat’ basis. Data
will be analysed by randomised group, irrespective of
whether the group received the intervention. Demo-
graphic and other baseline characteristics will be tabu-
lated. Descriptive statistics for continuous variables
will include the mean, standard deviation, median,
range, and number of observations. Categorical vari-
ables will be presented as numbers, and as percentages
of those participants who had the assessment. All sta-
tistics will be presented by treatment group. Effect
measures will be Relative Risk (RR) and absolute risk
reduction. Precision will be quantified using 95% con-
fidence intervals. Planned subgroup analyses include
analyses based on the severity of anaemia (moderate
versus severe) and type of labour (induced or aug-
mented versus spontaneous). In a large trial, such as
WOMAN-2, the baseline characteristics of partici-
pants that may influence the outcome are expected to
be evenly distributed between the treatment and pla-
cebo groups, so that any difference in outcome can be
attributed to the intervention. However, it is still pos-
sible that a chance imbalance in important prognostic
factors could influence the results. To investigate this
possibility, an analysis of the effect of treatment that is
adjusted for baseline risk will be conducted. A prog-
nostic model will be built based on pre-specified base-
line variables and use it to estimate the predicted risk
of the outcome at baseline. Checks will be made to en-
sure that there are sufficient patients in the severe an-
aemia subgroup by limiting recruitment to these
patients if necessary. For subgroups, RRs and confi-
dence intervals with two-sided P values will be re-
ported. Test of homogeneity of effect across the
subgroups will be done and a P value reported. Unless
there is evidence against the null hypothesis of homo-
geneity of effects the overall RR will be taken as the
most reliable guide to the approximate RR in all
subgroups.
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Regulatory issues
Approvals
Approval from the LSHTM Research Ethics Committee
(REC) has been obtained. Approval will be obtained
from the relevant RECs and regulatory authority of each
participating country. Where site approval is needed,
this will be obtained before the trial starts.
Confidentiality
Any identifiable data obtained by the CTU will be stored
securely and confidentiality protected in accordance with
the UK General Data Protection Regulation 2018. Local
investigators will collect consent, baseline, outcome and
adverse event data and will send them to the CTU. In-
vestigators will transmit data to the CTU by entering
them into the online trial database. Investigators will be
given a unique username, password and PIN to access
the database. The CTU will securely store copies of con-
sent forms sent for monitoring and these will be
destroyed at trial closure. Original copies of CRFs, con-
sent forms and source data will be kept securely at each
participating site. These must be archived securely for 5
years after the overall end of the trial. Only people
authorised by the project director/project manager will
have access to the WOMAN-2 trial database. The trial
database will be accessed through a complex password
system which includes a password ageing mechanism
(i.e. passwords will be changed every 90 days).
Indemnity
The LSHTM accepts responsibility attached to its spon-
sorship of the trial and, as such, would be responsible
for claims for any non-negligent harm suffered by any-
one as a result of participating in this trial. The indem-
nity is renewed on an annual basis and the LSHTM
assures that it will continue renewal of the indemnity for
the duration of this trial.
Sponsor
The London School of Hygiene and Tropical Medicine
(LSHTM) will act as the sponsor for this trial. Contact
details are provided in Additional file 7.
Funding
Wellcome (WT208870/Z/17/Z) and the Bill & Melinda
Gates Foundation (OPP1176150) are funding this study.
Women will not be paid for taking part as there is no
special travelling or time off work needed. A small prac-
tical gift as a ‘thank you’ will be given to women who
participate. The monetary value of the gift will not
exceed three British pounds. Where a woman returns to
hospital for any adverse event associated with the trial,
her travel costs will be reimbursed. Trial sites will be re-
imbursed for staff time and consumable costs associated
with the conduct of the trial. An agreement with each
site will be in place prior to the start of the trial.
Audits and inspections
The trial is subject to audit by the LSHTM under their
legal obligation as sponsor. Additionally, inspections can
be carried out by relevant RECs and other regulatory au-
thorities to ensure adherence to the protocol, GCP and
relevant regulations.
Trial management
Trial Management Group
A Trial Management Group (TMG) will be responsible
for overseeing the progress of the trial. The day-to-day
management of the trial will be coordinated through the
LSHTM CTU. The TMG will consist of the Protocol
Committee members plus a trial manager, data manager
and trial administrator.
The CTU will act on behalf of the sponsor and will be
responsible to the TMG to ensure that all of the spon-
sor’s responsibilities are carried out. The responsibilities
include (but are not limited to):
 Reporting to the Trial Steering Committee
 Maintaining the Trial Master File
 Identifying trial sites
 Assessing suitability of trial sites
 Confirming that all approvals are in place before
enrolment of participants and release of the trial
treatment
 Providing training about the trial, including site
initiation
 Providing study materials
 Data management
 24-h advice and un-blinding service
 Giving collaborators regular information about the
progress of the study
 Responding to any questions (e.g. from
collaborators) about the trial
 Communicating all important protocol
modifications to relevant parties
 Monitoring of the trial
 Ensuring data security and quality and observe data
protection laws
 Safety reporting
 Ensuring that the trial is conducted in accordance
with the ICH GCP
Statistical analysis
 publication of trial results.
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National coordination for each participating country
A national coordinating investigator will be identified for
each participating country. They will be responsible for
ensuring that all national approvals including those from
regulatory agencies, Ethics Committees and relevant im-
port licences are in place before the trial can start in their
country. Additionally, they will support the LSHTM CTU
with ensuring recruitment is on target, safety reporting to
all relevant agencies, and site training and monitoring as
required.
Protocol development
The Protocol Committee consists of the following inves-
tigators who will be responsible for the development of
and agreeing the final protocol. Subsequent changes to
the final protocol will require the agreement of the TSC:
 Sabaratnam Arulkumaran, Professor Emeritus of
Obstetrics and Gynaecology, St. George’s, University
of London, UK
 Imelda Bates, Professor, Liverpool School of Tropical
Medicine, Liverpool, UK
 Rizwana Chaudhri, Professor, Rawalpindi Medical
College, Pakistan (National Coordinating
Investigator, Pakistan)
 Bukola Fawole, Professor, University College
Hospital, Ibadan, Nigeria (National Coordinating
Investigator, Nigeria)
 Katharine Ker, Assistant Professor, Clinical Trials
Unit, LSHTM, London, UK
 Ian Roberts, Professor, Clinical Trials Unit, LSHTM,
London, UK (co-lead investigator)
 Haleema Shakur-Still, Associate Professor, Clinical
Trials Unit, LSHTM, London, UK (co-lead
investigator)
Independent DMC
The primary responsibility for monitoring the safety of
participants in the trial lies with the sponsor. This is
overseen by an independent DMC appointed to support
the safety monitoring. The composition of the DMC is
provided in Additional file 8.
The DMC will review on a regular basis accumulating
data from the ongoing trial and advise the TSC regard-
ing the continuing safety of current participants and
those yet to be recruited, as well as reviewing the validity
and scientific merit of the trial.
The DMC composition, name, title and address of the
chairman and of each member, will be given in the
DMC Charter which will be in line with that proposed
by the DAMOCLES Study Group [38]. Membership in-
cludes expertise in the relevant field of study, statistics
and research study design.
The DMC Charter includes, but is not limited to,
defining:
 The schedule and format of the DMC meetings
 The format for presentation of data
 The method and timing of providing interim reports
 Stopping rules
The DMC is independent from the sponsor, Ethics
Committees, regulatory agencies, investigators, Steering
Committee membership, clinical care of the trial partici-
pants, and any other capacity related to trial operations.
The DMC has the responsibility for deciding whether,
whilst randomisation is in progress, the un-blinded
results (or the un-blinded results for a particular sub-
group) should be revealed to the TSC. The DMC Char-
ter states that they will do this if, and only if, two
conditions are satisfied: (1) the results provide proof be-
yond reasonable doubt that treatment is on balance ei-
ther definitely harmful or definitely favourable for all, or
for a particular category of, participants in terms of the
major outcome and (2) the results, if revealed, would be
expected to substantially change the prescribing patterns
of clinicians who are already familiar with any other trial
results that exist. Exact criteria for ‘proof beyond reason-
able doubt’ are not, and cannot be, specified by a purely
mathematical stopping rule, but they are strongly influ-
enced by such rules. The DMC Charter is in agreement
with the Peto-Haybittle [39, 40] stopping rule whereby
an interim analysis of major endpoint would generally
need to involve a difference between treatment and con-
trol of at least three standard errors to justify premature
disclosure. An interim subgroup analysis would, of
course, have to be even more extreme to justify disclos-
ure. This rule has the advantage that the exact number
and timing of interim analyses need not be pre-specified.
In summary, the stopping rules require extreme differ-
ences to justify premature disclosure and involve an
appropriate combination of mathematical stopping rules
and scientific judgment.
Trial Steering Committee (TSC)
The TSC will include independent individuals and mem-
bers from the TMG. The composition of the TSC is pro-
vided in Additional file 9. The role of the TSC is to
provide supervision of the trial and to advise the spon-
sor. In particular, the TSC will concentrate on the pro-
gress of the trial, adherence to the protocol, participant
safety, and consideration of new information. The TSC
must be in agreement with the final protocol and,
throughout the trial, will take responsibility for:
 Major decisions such as a need to change the
protocol for any reason
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 Monitoring and supervising the progress of the trial
 Reviewing relevant information from other sources
 Considering recommendations from the DMC
 Informing and advising the TMG on all aspects of
the trial
The TSC includes an experienced obstetrician, clinical
trialists, lead investigators, clinical representative from a
LMIC, and a lay representative. Face-to-face meetings or
teleconferences will be held at regular intervals deter-
mined by need, but no less than once a year. A TSC
Charter, which will detail how it will conduct its busi-
ness, will be agreed at the first meeting.
Site PI’s responsibilities
Coordination within each participating hospital will be
through a site PI whose responsibility will be detailed in an
agreement in advance of starting the trial and will include:
 Personally supervising the study at site
 Before and if needed during the trial, obtain all
appropriate approval/favourable opinions
 Delegating trial-related responsibilities only to
suitably trained and qualified personnel
 Documenting delegation of duties to appropriately
qualified persons
 Training relevant medical, midwifery and nursing staff
to ensure that they remain aware of the state of the
current knowledge, the trial and its procedures (there
are wall charts, pocket summaries, training films and
PowerPoint presentations to assist with this)
 Agreeing to comply with the final trial protocol and
any relevant amendments
 Ensuring that all potentially eligible women are
considered promptly for the trial
 Ensuring that consent is obtained in line with local
approved procedures
 Ensuring that the data are collected and completed
and transmitted to the CTU in a timely manner
 Ensuring that all adverse events are reported
promptly to the CTU
 Ensuring that the Investigator’s Study File is up-to-
date and complete
 Accounting for trial treatments at their site
 Ensuring that the trial is conducted in accordance
with ICH GCP and fulfils all national and local
regulatory requirements
 Allowing access to source data, including participants’
medical records for monitoring, audit and inspection
 Being responsible for archiving all original trial
documents including medical records, Investigator’s
Study File, consent forms and data forms for at least
5 years after the end of the trial
Publication policy
All publications and presentations relating to the study
will be authorised by the lead investigators. Publications
will only contained anonymised data. We aim to publish
the main results of the WOMAN-2 trial in a peer-
reviewed journal under a CC-BY licence. This licence
will ensure that the publication is freely available and
can be distributed by others as long as they give credit
to the original creation. All publications will follow the
Consolidated Standards of Reporting Trials
(CONSORT) Statement. Links to publications will be
made in all applicable trial registers. The results will be
disseminated via the media, trial website and relevant
maternal health organisations. The main publication of
the trial results will be in the name of the Trial Collab-
orative Group (WOMAN-2 trial collaborators).
Discussion
The WOMAN-2 trial will provide reliable evidence for
the effects of TXA for preventing postpartum bleeding
in women with anaemia. If the WOMAN-2 trial shows
that TXA reduces PPH in anaemic women, we would
have identified a way of improving the wellbeing of
thousands of women world-wide.
Trial status
The current protocol is version 1.2, dated 10 July 2018.
The protocol was approved by the London School of
Hygiene and Tropical Medicine’s Ethics Committee (ref:
15194). National ethics and regulatory approvals are in
progress in three countries. Patient recruitment is
planned to start by January 2019. End of recruitment is
planned for January 2021 with end of follow-up in
March 2021. Further information is available at http://
woman2.lshtm.ac.uk/.
Additional files
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Additional file 2: World Health Organisation (WHO) trial registration
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